Przejdź do treściGeneral Medical Discoveries · Early human study
Researchers have reported early results from a method designed to generate CD19 CAR-T cells directly inside the patient using a lentiviral vector, rather than first collecting and modifying cells in a laboratory. Among 16 people with treatment-refractory neurologic autoimmune disorders, the study reported complete B-cell depletion, manageable side effects and preliminary clinical improvement across disease groups. The approach is interesting because it could eventually simplify CAR-T treatment, which is best known from oncology. An orthopaedic surgeon following developments in cell therapy should note that, for now, this is a small early report rather than evidence from a large controlled trial, so larger controlled studies are needed before it can be considered established treatment.
Source: Cheng Y-H, et al. Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders. New England Journal of Medicine. Published online 2 September 2026;395:926–929. DOI: 10.1056/NEJMc2603114 · PubMed. Access used for this summary: article page and abstract; bibliographic metadata checked in PubMed on 15 September 2026.
More General Medical Discoveries · Polish version
Content prepared by: Tomasz Poboży - orthopaedic surgeon.